|
Serenoa repens Bartram, (Arecaceae). Previously Serenoa serrulata and Sabal
serrulata (Palmae, Palmaceae) Common name is saw palmetto.
History: Serenoa, being indigenous to the Southeastern United States,
has a short medicinal history. The Native Americans and early settlers used
the berry for food and medicine, believing it to be strengthening to the system.
The center core of the fan palm plant was in great demand for was eating and
considered delicious.
The Eclectics of the 18th century were using Serenoa for upper and
lower respiratory problems, atrophy of the breast, ovaries and testes and for
BPH. It was also used as an aphrodisiac. The berries were official in the
United States Pharmacopoeia from 1906 to 1916, and in the National
Formulary from 1926 to 1950.
During the 1960s, it was discovered that there were relatively high concentrations
of free and bound sitosterols in the dried berries. b-sitosterols
and other Serenoa extracts injected into female mice showed fairly high activity,
compared to other plant estrogens.1 Since
that time Serenoa has been extensively studied in Europe for treatment of BPH
and for the chemical explanation of its efficiency.
Serenoa belongs to the palm fans (Arecaceae), and S. repens is the only species
within its genus. It is a shrub or small tree that grows up to ten feet, with
a crown of large, fan-like leaves and a reddish to blackish berry about the
size of an olive. It is native to the Southeastern United States from Southern
Carolina to Southeastern Louis
The ripe berry is the part used. Serenoa is available as a bulk herb, but
the active ingredients are not water soluble, so a tea would be ineffective
for most purposes. The studies have all used a liposterolic extract prepared
primarily with hexane. Liposterolic extracts can also be prepared with 90%
ethanol or by a supercritical carbon dioxide process. The extract should contain
85 to 95% fatty acids and 0.2 to 0.4% total sterols. It is also available in
hydroalcoholic extracts and capsules.
Serenoa has received a great deal of attention as a treatment for early stages
of benign prostatic hyperplasia (BPH.) There are a number of pharmacodynamic
effects, suggesting multiple mechanisms of action that give the favorable results
in BPH. These are primarily inhibition of 5 alpha-reductase2,3 and the binding of androgen receptors
(testosterone, but also estrogen and progesterone indicating antiestogenic effect.)4,5
Studies have determined it does help with dysuria, nocturia, frequency of urination
and other urinary difficulties.6 It has some anti-inflammatory action7
and spasmolytic activity. Serenoa has compared favorably with finasteride,8 with less
side effects. There is some evidence that Serenoa does reduce the size of the
prostate.9,10.
It is most commonly used for treatment of BPH, but contemporary herbals also
recommend it for asthma, bronchitis, wasting conditions, impotence and frigidity.
The berries contain approximately 1.5 percent essential oil, of which 63 percent
are free fatty acids and 38 percent are ethyl esters of those fatty acids.
The fatty acids include: caproic, capric, lauric, palmitic and oleic acids,
and ethyl esters of these. They also contain b-sitosterol and
its glucoside, b-sitosterol D-glucoside, as well as ferulic acid.11
The liposterolic extract dosage is 160 mg twice a day.
This would correspond to about 3 or 4 g of dried berries per day. Men
using Serenoa for BPH should consult with his health care professional on a
regular basis. The mechanism of action is similar to finasteride and there could
be an additive effect, therefore, it is not recommended to use them concurrently.
It is possible that the antiandrogenic actions of Serenoa may diminish the
effects of therapeutic androgens.
No significant side effects have been reported in clinical
studies except for occasional upset stomach. It is not recommended during
pregnancy.
1 Tyler, Varro
E, Phd. The Honest Herbal. The Pharmaceutical Press. New York.
1993. 285-7.
2 Sultan C, Terraza
A, Devillier C, et al. “Inhibition of androgen metabolism and binding by
a liposterolic extract of “Serenoa repens B” in human foreskin fibroblasts”.
Journal of Steroid BioChemistry:20(1). Jan 1984. 515-9.
3 Plosker GL,
Brogden RN. “Serenoa repens (Permixon). A review of its pharmacology and
therapeutic efficacy in benign prostatic hyperplasia”. Drugs and Aging:
9(5). Nov 1996. 379-95.
4 Di Siverio
F, D’Eramo G, Lubrano, et al. “Evidence that Serenoa repens displays and
antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy
patients”. European Urology: 21(4). 1996. 309-14.
5 Ravenna L,
Di Silverio F, Russo MA, et al. “Effects of the Lipidosterolic Extract of
Serenoa Repens (Permixon) on Human Prostatic Cell Lines”. The Prostate:
29(4). Oct 1996. 219-230.
6 Romics I, Schmitz
H, Frang D. “Experience in Treating Benign Prostatic Hypertrophy with Sabal
serrulata for One Year”. International Urology and Nephrology: 25(6).
1993. 565-69.
7 Paubert-Braquet
M, Mencia Heuetra JM, et al. “Effect of the lipidic lipidosterolic extract
of Serenoa repens (Permixon) on the ionophore A23187-stimulated production
of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils”. Prostaglandins
Leukotrienes and Essential Fatty Acids: 57(3). Sept 1997.299-304.
8 Carroaro JC,
Raynaud JP, Kock G, et al. “Comparison of phytotherapy (Permixon) with finasteride
in the treatment of benign prostate hyperplasia: a randomized international
study of 1,098 patients”. The Prostate: 29(4). Oct 1996. 241-2.
9 Paurbert-Braquet
M, Richardson FO, et al. “Effect of Serenoa repens extract (Permixon) on
extradiol/testosterone-induced experimental prostate enlargement in the rat”.
Pharmacological Resident: 34(3-4). Sept-Oct 1996. 179.
10 Romics I,
Schmitz H, Frang D. “Experience in Treating Benign Prostatic Hypertrophy
with Sabal serrulata for One Year”. International Urology and Nephrology:
25(6). 1993. 565-69.
11 Duke JA.
Handbook of Medicinal Herbs. Boca Raton. FL. 1985. 443.
|